Novo Nordisk’s stock tumbles as doubts persist about Ozempic maker’s goals for 2030
The weight-loss-drug manufacturer failed to excite investors hoping for a turnaround.
Markets
Novo Nordisk’s stock tumbles as doubts persist about Ozempic maker’s goals for 2030
Read also
Markets
Global stock markets bounce higher; government bond yields tumble as oil slides – business live
Business
Building an investment portfolio on Auxingroup.com: multi-asset coverage, 1:20 leverage and real-time analytics
Markets
Nissan eyes increasing U.S. production as new Rogue hybrid launches
Markets